Ionis Gains EU Approval for Tryngolza in Severe Hypertriglyceridemia
Ionis Pharmaceuticals said the European Commission approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia, or sHTG. The approval covers use alongside diet and other lipid-lowering treatments in patients with fasting triglyceride levels of ≥880 mg/dL (≥10 mmol/L).
Ionis announced the decision on 2026-11-17, saying it broadens Tryngolza's availability in Europe. The company said the therapy is the first RNA-targeted medicine cleared in the EU for this adult group, and the only one.
Important questions to consider
It is approved for adult patients with severe hypertriglyceridemia, defined by fasting triglyceride levels of ≥880 mg/dL (≥10 mmol/L). It is to be used alongside diet and other lipid-lowering therapies.
Ionis said Tryngolza is the first RNA-targeted medicine cleared in the EU for adults with sHTG at the ≥880 mg/dL (≥10 mmol/L) threshold, and the only one. The company also said the approval broadens the drug's availability in Europe.
Ionis announced the approval on 2026-11-17. The company said the decision covers use of Tryngolza in adults with sHTG.
Sources
- Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
Zacks Investment Research
- TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
GuruFocus
- TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
Business WirePress release